| Dataset / population | Location / diagnosis years | Key epidemiology statistics | Key survival statistics | Source |
|---|---|---|---|---|
| CBTRUS Statistical Report: all primary brain and other CNS tumors, with glioma-relevant subset | United States; diagnosed 2017-2021 | Gliomas accounted for **22.9%** of all primary brain/CNS tumors. Glioblastoma accounted for **14.0% of all tumors** and **51.5% of all malignant tumors**. Overall malignant brain/CNS tumor incidence was **6.89 per 100,000**; by sex, **8.06 per 100,000 in males** vs **5.84 per 100,000 in females**. Malignant brain/CNS tumor mortality was **4.41 per 100,000** (average annual mortality), with **87,053 deaths** during 2017-2021. (pqac-00000013) | **5-year relative survival for malignant brain/CNS tumors: 35.7%**. (pqac-00000013) | Price et al., *Neuro-Oncology* 2024, published Oct 2024. https://doi.org/10.1093/neuonc/noae145 |
| Belgian population-based adult-type diffuse glioma registry | Belgium; diagnosed 2017-2019 | **2,233** adult-type diffuse gliomas identified; **40.1% female**; median age **64 years**. Age-standardized incidence rate (ASR) for diffuse adult-type glioma: **8.55 per 100,000 person-years**. ASR for grade 4 lesions: **6.72 per 100,000 person-years**. (pqac-00000009, pqac-00000011) | **Median OS 9.3 months** for IDH-wildtype glioblastoma; **25.9 months** for grade 4 IDH-mutant astrocytoma. **3-year survival**: IDH-mutant astrocytoma grade 2 **86.0%**, grade 3 **75.7%**; IDH-wildtype astrocytoma grade 2 **31.6%**, grade 3 **5.7%**; oligodendroglioma grade 2 **93.4%**, grade 3 **64.2%**; grade 4 lesions overall **6.5%**. (pqac-00000009, pqac-00000011) | Pinson et al., *Neuro-Oncology* 2024, published Aug 2024. https://doi.org/10.1093/neuonc/noad158 |
| Belgian registry contextual comparison with prior US glioblastoma incidence estimate | Belgium study citing US data; US comparator largely 2015-2019 | Study notes CBTRUS-reported glioblastoma ASR in the US population of **3.26 per 100,000 person-years**. (pqac-00000008) | Provides context that real-world glioblastoma outcomes remain poor relative to molecularly favorable diffuse glioma subtypes. (pqac-00000008) | Pinson et al., *Neuro-Oncology* 2024. https://doi.org/10.1093/neuonc/noad158 |


*Table: This table compiles recent population-level glioma epidemiology and survival figures from the 2024 CBTRUS report and a 2024 Belgian molecular-era registry. It is useful for contrasting broad U.S. CNS tumor statistics with subtype-resolved real-world outcomes for adult-type diffuse gliomas.*